The Kratom Council

Latest / Regulation

Regulation

North Dakota Wrote The Federal Threshold Into Its Own Statute. On Wednesday That Federal Proposal Was Not Replaced. It Was Withdrawn.

A dark charcoal slate slab photographed from directly overhead, with two shallow rectangular recesses cut into its surface. The left recess holds a smooth pale grey tile sitting flush inside it. The right recess is empty, showing bare stone at its base, and a second pale grey tile lies on the slab surface beside it, out of its recess.

On Wednesday the Drug Enforcement Administration published two notices of intent in the Federal Register. Between them they do opposite things. One proposes a threshold for two compounds. The other reissues a control on two different compounds with no threshold at all. And a third document in the same issue withdraws the proposal this industry has measured itself against since July.

The withdrawal is the smallest item of the three and the most consequential.

What Published, And What Each Document Does

The threshold notice carries Federal Register document number 2026-20943 and the docket number DEA-1570, the same docket as July. As reported, its title names 7-hydroxymitragynine and mitragynine pseudoindoxyl together, and it proposes to place either substance, or the two combined, in Schedule I above a specified threshold. It follows a letter from the Department of Health and Human Services dated October 8.

The notice sets out two tests joined by or. The first is a concentration, reaching a substance present at "greater than 1 mg per gram (for solid powders, encapsulated material, or other solid forms) or greater than 1 mg per milliliter (for liquid preparations)." The second is a ratio, reaching the case where "the mass of mitragynine present divided by the mass of" the controlled substance or substances "is less than 100." A product that clears one test and fails the other would still fall inside the proposed listing.

The second notice, document number 2026-20942, covers MGM-15 and MGM-16 and proposes no threshold for them. On the reporting available the reason is a separate letter from the same department, dated October 6, which did not recommend controlling those two substances above any threshold. The agency states that this does not change the findings it had already made about them. Both notices describe an order that would run two years, with a possible one-year extension, while permanent scheduling is considered.

The third document is the one that resets the record. The threshold notice states that "in a separate document contained in this issue of the Federal Register" the agency is withdrawing the notice of intent published on July 6.

Withdrawn Is Not The Same As Replaced

A superseded proposal is still the agency's last word until the new one takes its place. A withdrawn proposal is removed. The agency is no longer proposing it, and there is no version of the future in which it becomes the rule.

For fifteen weeks the figure in that July notice was the only federal number in existence for this compound: 0.050 per cent by weight, or more than one milligram in an article. It was the number in compliance memos, in certificates of analysis, in state bills, and in this publication's own reporting. On Wednesday it stopped being a proposal at all.

Nothing about that is a loosening or a tightening. The July number is simply no longer on the table, and the new notice starts its own clock.

One State Had Already Written It Down

This publication reported in September that North Dakota had adopted the federal threshold into state law while the federal order itself had not issued. The oddity then was a state codifying a number the agency proposing it had not yet imposed.

That oddity has now changed character. The number North Dakota wrote into its code is the number the agency withdrew on Wednesday. The state statute is not affected by that. It is state law, enacted by a legislature, and a federal withdrawal does not reach into a state code and edit it. What changed is the reference point. North Dakota's figure was drafted to match a federal proposal, and the federal proposal it matched no longer exists.

North Dakota's legislature is not in session continuously, and this publication has not established whether anyone in the state has raised the point. What can be said is narrow and worth saying precisely. A state that aligned itself with a federal number now holds that number alone.

Three Letters In Three Days, And They Do Not Say The Same Thing

The more useful finding in Wednesday's documents is what they reveal about what the health department actually decided.

On the reporting available there are three separate communications in the space of four days. A letter dated October 6 declined to recommend a threshold for MGM-15 and MGM-16. A letter dated October 8 recommended one for 7-hydroxymitragynine and mitragynine pseudoindoxyl. A public announcement followed on October 9.

That is not one policy applied across a category. It is a compound-by-compound determination that reached different answers for different molecules in the same family, and the two notices published on Wednesday carry those different answers side by side. An operator reading only the headline figure would take away a single federal rule for enhanced kratom products. The documents describe something narrower and more specific than that.

This publication reported in October that the shape of the federal test had changed from an amount to an amount and a ratio. Wednesday's documents are the first filing of that change, and they also show it does not extend to every compound the agency has moved against.

One Compound Moved In The Other Direction

Mitragynine pseudoindoxyl is worth following on its own.

On August 26 it was placed in Schedule I by a temporary order with no concentration threshold attached. In the notice's words, that order "remains in effect until either it expires or the new temporary order is published and the previous order is withdrawn, whichever occurs first." The notice published on Wednesday names that same compound in its title and proposes to control it above a threshold.

So a substance currently controlled without qualification is the subject of a proposal to control it conditionally. This publication is not going to characterise what that means for anyone's inventory, because the order has not issued. The sequencing between the two instruments is no longer a matter of inference, though. The notice states it directly, and the sentence quoted above is the whole of it.

What The Order Would Reach

What a temporary order would control is wider than the question of what sits on a shelf. On the notice's account the order would apply the controls and the administrative, civil and criminal sanctions attaching to Schedule I substances to anyone who handles, or proposes to handle, either substance above the threshold. Handling is enumerated rather than left general: to manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess. Research, teaching, analysis and plain possession sit in that list beside manufacture and distribution.

The notice is also explicit that nothing in it amounts to a safety finding. Readers, it says, "should not infer from this notice of intent that DEA views 7-hydroxymitragynine or mitragynine pseudoindoxyl below this threshold as safe for consumption." That is the agency's position, not adopted here. This article previously attributed that statement to both departments rather than to the agency, which the document's own wording does not support.

What Has Not Happened

The temporary scheduling order for 7-hydroxymitragynine still has not issued. What published on Wednesday is notice of an intent to issue one.

The notice prints the date itself. It states that the temporary scheduling order "will be published in the Federal Register on or after November 13, 2026." Thirty days from October 14 is November 13.

One further detail is worth knowing for anyone searching the record. The Federal Register is reported to classify the threshold notice as a proposed rule, while the document itself is a notice of intent. The two labels describe the same filing.

There is also a correction this publication owes its own readers. Our October 12 article reported that the health department sent its recommendation on October 9. The notice published Wednesday dates that letter October 8. October 9 was the public announcement. The substance of the recommendation is unchanged and is confirmed by Wednesday's filing.

Sourcing, Plainly

This article was first published on October 15 with nothing retrieved. The Federal Register, govinfo and the Federal Register public inspection service were all unreachable from this publication's working environment, so neither notice was opened and neither was read, and the piece carried no quotation marks anywhere for that reason.

It has since been updated, and the distinction matters. Every passage now inside quotation marks is the language of document 2026-20943 itself, supplied to this publication from the document by a person who had it open, and reproduced rather than paraphrased. Everything outside quotation marks still rests on search results reporting the contents of the two notices. This publication still has not opened either document. Its working environment still cannot reach the Federal Register.

The document numbers, the publication date, the docket number, the two titles and the fact of the July withdrawal are consistent across the results and are treated here as established. The letter dates of October 6 and October 8 come from descriptions of the notices themselves and are the load-bearing new facts in this article. Anyone making a commercial decision should read both notices directly before relying on any figure in this piece.

One correction to this article's own reasoning. As first published it declined to adopt a characterisation, reported elsewhere, that the companion notice was reissued on procedural grounds, on the ground that this did not match the reason the document was reported to give. The document's own language says that the notice serves "only" the "technical and procedural purpose of distinguishing MGM-15 and MGM-16 from mitragynine pseudoindoxyl." The characterisation this article set aside was the document's own. The October 6 letter declining to recommend a threshold for those two compounds is also real, and the two are not in conflict.

Sources

  1. Reporting on the two Federal Register notices of intent published October 14, 2026, as it appears in search results, together with the text of document 2026-20943 as supplied to this publication from the document itself. Neither document was reachable from this publication's working environment and neither was opened here. Passages in quotation marks are the supplied document text.
  2. Federal Register — Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I, Docket No. DEA-1570, document 2026-20943 (October 14, 2026)
  3. Federal Register — Temporary Placement of MGM-15 and MGM-16 in Schedule I, document 2026-20942, 91 FR 65381 (October 14, 2026)
  4. govinfo — Federal Register Vol. 91, No. 197, document 2026-20943 (October 14, 2026)
  5. govinfo — Federal Register Vol. 91, No. 197, document 2026-20942 (October 14, 2026)
  6. Federal Register — the withdrawn notice of intent of July 6, 2026, 91 FR 40917, document 2026-13580
  7. Department of Health and Human Services — announcement of recommended thresholds for enhanced kratom products (October 9, 2026)
  8. The Kratom Council — "For Fifteen Weeks The Trade Watched One Number"
  9. The Kratom Council — "North Dakota Adopted The Federal Threshold The DEA Has Not Issued"
  10. The Kratom Council — "What The August 26 Scheduling Order Actually Covers, And What It Does Not"
  11. The Kratom Council — "DEA Schedules Three 7-OH Analogs As The 7-OH Order Waits"

← Back to all coverage

Get new reporting by email